Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4648003 | 1.00 | KMT2A (0.51) | KMT2AMEN1ATMALDH1A1CHRNA7 | |
| SCHEMBL15615152 | 0.83 | PDE1B (0.43) | HRH4HRH3MLNR | |
| SCHEMBL611124 | 0.79 | KMT2A (0.51) | KMT2AMEN1ATMALDH1A1CHRNA7 | |
| SCHEMBL18320629 | 0.78 | MLNR (0.41) | HRH4HRH3MLNR | |
| SCHEMBL5044718 | 0.78 | ALDH1A1 (0.68) | KMT2AMEN1ATMALDH1A1CHRNA7 | |
| SCHEMBL4592039 | 0.77 | HRH3 (0.63) | KMT2AMEN1ATMALDH1A1CHRNA7 | |
| SCHEMBL20803929 | 0.76 | MLNR (0.47) | ALDH1A1LMNAHRH4HRH3MLNR | |
| SCHEMBL12499778 | 0.76 | SIGMAR1 (0.48) | ALDH1A1HRH4HRH3MLNR | |
| SCHEMBL3396309 | 0.76 | LMNA (0.51) | ALDH1A1LMNAHRH4HRH3MLNR | |
| SCHEMBL5059571 | 0.76 | MLNR (0.56) | HRH4HRH3MLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964602-B2 | Biaryl compounds useful as agonists of the Gpr38 receptor | GLAXO GROUP LIMITED (GB) | 2011-06-21 | — | — | US | disclosed |
| EP-1960390-B1 | BIARYL COMPOUNDS USEFUL AS AGONISTS OF THE GPR38 RECEPTOR | GLAXO GROUP LTD (GB) | 2010-07-21 | — | — | EP | disclosed |
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GLAXO GROUP LIMITED | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306083-A1 | Biaryl Compounds Useful as Agonists of the Gpr38 Receptor | GPR88, GPR68, GPBAR1 | KMT2A 3883/4885MEN1 3916/4885ATM 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.